Le médicament du mois Le voriconazole (Vfend).

Antifungal Agents/chemistry/pharmacology; Drug Interactions; Humans; Molecular Structure; Pyrimidines/chemistry/pharmacology; Triazoles/chemistry/pharmacology

Abstract :

[en] Invasive fungal infections are a rare but important cause of morbidity and mortality among patients with severely compromised host defenses. Despite considerable advances in antifungal therapies over the past years, invasive mycoses remain a stubborn and dramatic problem. Voriconazole is a new triazole antifungal agent which confers a relative survival benefit in fluconazole-resistant invasive candidiasis, and in invasive aspergillosis, fusariosis and Scedosporium infections as well.

Disciplines :

Dermatology

Author, co-author :

Pierard, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Arrese Estrada, Jorge ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Quatresooz, Pascale ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Pierard, Claudine ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Language :

French

Title :

Le médicament du mois Le voriconazole (Vfend).

Alternative titles :

[en] Drug of the month. Voriconazole (Vfend).

Publication date :

2003

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

351-5

Peer reviewed :

Peer reviewed

Available on ORBi :

since 12 March 2009

Statistics

Number of views

184 (2 by ULiège)

Number of downloads

186 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Arrese JE, Piérard-Franchimont C, Ghazi A, Piérard GE. - Mycoses cutanées tropicales. Rev Med Liège, 2000, 55, 586-590.
Quatresooz P, Arrese JE, Piérard GE. - Synopsis des dermatomycoses invasives chez l'immunodéprimé. Rev Med Liège, sous presse.
Pièrard GE, Read D, Piérard-Franchimont C, et al. - Cutaneous manifestations in systemic trichosporonosis. Clin Exp Dermatol, 1992, 17, 79-82.
Arrese JE, Piérard-Franchimont C, Piérard GE. - Fatal hyalohyphomycosis following Fusarium onychomycosis in an immunocompromised patient. Am J Dermatopathol, 1996, 18, 1296-1298.
Arrese JE, Piérard-Franchimont C, Piérard GE. - Onychomycosis and keratomycosis caused by Alternaria sp. A bipolar opportunistic infection in a wood-pulp worker on chronic steroid therapy. Am J Dermatopathol, 1996, 18, 611-613.
Quatresooz P, Meiers I, Arrese JE, et al. - Fusariose disséminée chez un patient immunodéprimé. Rev Med Liège, 2000, 55, 974-976.
Sobel JD, for the Mycoses Study Group. - Practice guidelines for the treatment of fungal infections. Clin Infect Dis, 2000, 30, 652.
Quatresooz P, Dethier F, Piérard GE. - Chromomycose autochtone chez une patiente immunodéprimé. Dermatol Actual, sous presse.
Wingard JR. - Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis, 1995, 20, 115-125.
Rex JH, Walsh TJ, Anaissie EJ. - Fungal infections in iatrogenically compromised hosts. Adv Intern Med, 1998, 43, 321-371.
Denning DW - Invasive aspergillosis. Clin Infect Dis, 1998, 26, 781-803.
De Pauw BE, Meis JFGM. - Progress in fighting systemic fungal infections in haematological neoplasia. Support Care Cancer, 1998, 6, 31-38.
Lin SJ, Schranz J, Teutsch SM. - Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis, 2001, 32, 358-366.
Ascioglu S, Rex JH, de Pauw B, et al., on behalf of the Invasive Fungal Infections Cooperative Group of the Europan Organization for Research and Treatment of Cancer and Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. - Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis, 2002, 34, 7-14.
Piérard GE, Arrese JE, Piérard-Franchimont C, et al. Immunohistochemical expression of galactomannan in the cytoplasm of phagocytic cells during invasive aspergillosis. Am J Clin Pathol, 1991, 96, 373-376.
Arrese JE, Stynen D, Van Cutsem J, et al. - Immunohistochemical identification of Penicillium marneffei by monoclonal antibody. Int J Dermatol, 1992, 31, 410-412.
Fukuzawa M, Inaba H, Hayama M, et al. - Improved detection of medically important fungi by immunoperoxidase staining with polyclonal antibodies. Virchows Arch, 1995, 427, 407-414.
Darcis JM, Etienne M, Demonty J, et al. - Candida albicans septicemia with folliculitis in heroin addicts. Am J Dermatopathol, 1986, 8, 401-504.
Warnock DW. - Fungal infections in neutropenia: current problems and chemotherapeutic control. J Antimicrob Chemother, 1998, 41, suppl D, 95-105.
Ponton J, Rüchel R, Clemons KV, et al. - Emerging pathogens. Med Mycol, 2000, 38 suppl 1, 225-236.
Carrillo AJ, Guarro J. - In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother, 2001, 45, 2151-2153.
Banerjee SN, Emori G, Culver DH, et al. and the National Nosocomial Infections Surveillance System. Secular trends in nosocomial primary bloodstream infections in the United State, 1980-1989. Am J Med, 1999, 91 suppl 3B, 86S-89S.
Edmond MB, Wallace SE, McClish DK, et al. - Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis, 1999, 29, 239-244.
Viscoli C, Gimenia C, Marinus A, et al. and the Invasive Fungal Infection Group of the EORTC. - Candidemia in cancer patients: a prospective, multicenter surveillance study by the invasive fungal infection group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Cin Infect Dis, 1999, 28, 1071-1079.
Rex JH, Walsh TJ, Sobel JD, et al. - Practice guidelines for the treatment of candidiasis. Clin Infect Dis, 2000, 30, 662-678.
Pfaller MA, Diekema DJ, Jones RN, et al. and the SENTRY Participant Group. - International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol, 2001, 39, 3254-3259.
Safdar A, Chaturved V, Cross EW, et al. - Prospective study of Candida species in patients at a comprehensive cancer center. Antimicrob Agents Chemother, 2001, 45, 2129-2133.
Manuel RJ, Kibbler CC. - The epidemiology and prevention of invasive aspergillosis. J Hosp Infect, 1998, 39, 95-109.
Denning DW, Ribaud P, Milpied N, et al. - The efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis, 2002, 34, 563-571.
Patterson DL, Singh N. - Invasive aspergillosis in transplant recipients. Medicine, 1999, 78, 123-138.
Patterson TF, Kirkpatrick WR, White M, et al. for the 13 Aspergillus Study Group. - Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine, 2000, 79, 250-260.
Arrese Estrada J, Piérard-Franchimont C, Soyeur-Broux M, Piérard GE. - L'aspergillose cutanée. Rev Med Liège, 1991, 46, 92-97.
Denning DW. - Therapeutic outcome in invasive aspergillosis. Clin Infect Dis, 1996, 23, 608-615.
Sampathkumar P, Paya CV. - Fusarium infection after solid-organ transplantation. Clin Infect Dis, 2001, 32, 1237-1240.
Boutati EL, Anaissie EJ. - Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood, 1997, 90, 999-1008.
Martino P, Gastaldi R, Raccah R, Girmenia C. - Clinical patterns of Fusarium infections in immuncompromised patients. J Infect, 1994, 28 suppl 1, 7-15.
Idigoras P, Pérez-Trallero E, Pineiro L, et al. - Disseminated infections and colonization by Scedosporium prolificans: a review of 18 cases, 1990-1999. Clin Infect Dis, 2001, 32, 2158-2165.
Ender PT, Dolan MJ. - Pneumonia associated with near-drowning. Clin Infect Dis, 1997, 25, 896-907.
Nesky MA, McDougal EC, Peacock JE. - Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis. Clin Infect Dis, 2000, 31, 673-677.
Sanati H, Belanger P, Fratti R, Ghannoum M. - A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother, 1997, 41, 2492-2496.
Espinel-Ingroff A. - In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol, 1998, 36, 198-202.
Johnson EM, Szekely A, Warnock DW. - In vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother, 1998, 42, 741-745.
Cuenca-Estrella M, Diaz-Guerra TM, Mellado E, et al. - Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain. Eur J Clin Microbiol Infect Dis, 1999, 18, 432-435.
Kappe R. - Antifungal activity of the new azole UK-109,496 (voriconazole). Mycosis, 1999, 42 suppl 2, 83-86.
Koul A, Vitullo J, Reyes G, Ghannoum M. - Effects of voriconazole on Candida glabrata in vitro. JAntimicrob Chemother, 1999, 44, 109-112.
Sabo JA, Abdel-Rahman SM. - Voriconazole: a new triazole antifungal. Ann Pharmacother, 2000, 34, 1032-1043.
Chandrasekar PH, Manavathu E. - Voriconazole: a second-generation triazole. Drugs Today, 2001, 37, 135-148.
Groll AH, Walsh TJ. - Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect, 2001, 7, suppl 2, 8-24.
Groll AH, Piscitelli SC, Walsh TJ. - Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol, 1998, 44, 343-500.
Herbrecht R, Denning DW, Patterson TF, et al. - Voriconazole versus amphotericine B for primary therapy of invasive aspergillosis. N Engl J Med, 2002, 347, 408-415.